early mobilisation

Oncology

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

Patients

Four key trends and innovations catalysing infusion therapy ...

IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the

Digital

pharmaphorum podcast Episode 231, Dr Alan Roth, Oxford Drug Design

On AI and computational support of biochemistry, with Alan R...

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

Sales & Marketing

The AI imperative: Establishing the standard for modern clin...

The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.

Editor's Picks